Literature DB >> 27572131

Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon.

R Sekar1, K Singh1, A W R Arokiaraj1, B K C Chow2.   

Abstract

Glucagon family of peptide hormones is a group of structurally related brain-gut peptides that exert their pleiotropic actions through interactions with unique members of class B1 G protein-coupled receptors (GPCRs). They are key regulators of hormonal homeostasis and are important drug targets for metabolic disorders such as type-2 diabetes mellitus (T2DM), obesity, and dysregulations of the nervous systems such as migraine, anxiety, depression, neurodegeneration, psychiatric disorders, and cardiovascular diseases. The current review aims to provide a detailed overview of the current understanding of the pharmacological actions and therapeutic advances of three members within this family including glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP), and glucagon.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  gastric inhibitory polypeptide; glucagon; glucagon-like peptide-1; pharmacology; type-2 diabetes mellitus

Mesh:

Substances:

Year:  2016        PMID: 27572131     DOI: 10.1016/bs.ircmb.2016.05.002

Source DB:  PubMed          Journal:  Int Rev Cell Mol Biol        ISSN: 1937-6448            Impact factor:   6.813


  7 in total

1.  Differences in Metabolic Factors Between Antipsychotic-Induced Weight Gain and Non-pharmacological Obesity in Youths.

Authors:  Simone Pisano; Giangennaro Coppola; Gennaro Catone; Marco Carotenuto; Raffaella Iuliano; Vittoria D'Esposito; Serena Cabaro; Emanuele Miraglia Del Giudice; Carmela Bravaccio; Pietro Formisano
Journal:  Clin Drug Investig       Date:  2018-05       Impact factor: 2.859

2.  Effects of site-directed mutagenesis of GLP-1 and glucagon receptors on signal transduction activated by dual and triple agonists.

Authors:  Sanaz Darbalaei; Ru-Lue Chang; Qing-Tong Zhou; Yan Chen; An-Tao Dai; Ming-Wei Wang; De-Hua Yang
Journal:  Acta Pharmacol Sin       Date:  2022-08-11       Impact factor: 7.169

3.  Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide.

Authors:  Rulue Chang; Xin Zhang; Anna Qiao; Antao Dai; Matthew J Belousoff; Qiuxiang Tan; Lijun Shao; Li Zhong; Guangyao Lin; Yi-Lynn Liang; Limin Ma; Shuo Han; Dehua Yang; Radostin Danev; Ming-Wei Wang; Denise Wootten; Beili Wu; Patrick M Sexton
Journal:  J Biol Chem       Date:  2020-05-05       Impact factor: 5.157

Review 4.  The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence.

Authors:  Mohammed Altigani Abdalla; Harshal Deshmukh; Stephen Atkin; Thozhukat Sathyapalan
Journal:  Ther Adv Endocrinol Metab       Date:  2021-01-27       Impact factor: 3.565

Review 5.  G protein-coupled receptors: structure- and function-based drug discovery.

Authors:  Dehua Yang; Qingtong Zhou; Viktorija Labroska; Shanshan Qin; Sanaz Darbalaei; Yiran Wu; Elita Yuliantie; Linshan Xie; Houchao Tao; Jianjun Cheng; Qing Liu; Suwen Zhao; Wenqing Shui; Yi Jiang; Ming-Wei Wang
Journal:  Signal Transduct Target Ther       Date:  2021-01-08

Review 6.  Therapeutic peptides: current applications and future directions.

Authors:  Lei Wang; Nanxi Wang; Wenping Zhang; Xurui Cheng; Zhibin Yan; Gang Shao; Xi Wang; Rui Wang; Caiyun Fu
Journal:  Signal Transduct Target Ther       Date:  2022-02-14

7.  Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome.

Authors:  Chuan Xing; Han Zhao; Jiaqi Zhang; Bing He
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-17       Impact factor: 6.055

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.